Optimi Health Sets 2027 Clinical Agenda; Expects First Ibogaine Capsules Soon

Optimi Health (OPTH) outlined 2027 clinical trials for OPTI-101 (psilocybin for MDD) and OPTI-201 (MDMA for PTSD). Phase 2b and 3 trials planned, with U.S. IND applications expected. Ibogaine capsule production to begin soon. Proposed shares-for-debt settlement of US$240,000. OPTH stock is down 5.06% to $1.96.

Original reporting
Published Nov 18, 2026, 6:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 6:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Optimi Health Sets 2027 Clinical Agenda; Expects First Ibogaine Capsules Soon — source image
Decision brief

The 30-second read

$OPTHNeutralMed
01

Why it matters

The amended Phase 2b design for OPTI-101 (controlled trial with an active placebo) and the planned Phase 3 for OPTI-201 provide clearer development milestones, while the shares-for-debt settlement introduces potential dilution and governance considerations. Both factors can influence risk appetite and valuation for OPTH ahead of future regulatory and trial execution steps.

02

Market read

Traders may reprice OPTH based on the specificity of trial designs, expected dosing/topline windows, and the concrete proposed share issuance tied to unpaid compensation.

03

What to watch

The proposed shares-for-debt settlement at a fixed $2.10/share could be a near-term dilution signal, and the related-party nature may raise governance scrutiny even if approvals are routine.

Relevance 7/10Novelty 6/10Timing: planning details for 2027 trials, with dosing expected in Q1 2027 and settlement shares pending approvals

Background

Optimi is developing psychedelic-based therapies (psilocybin for MDD, MDMA for PTSD, and ibogaine capsules for prospective research) and is updating its clinical roadmap for 2027.

Company-level read

Ticker impact

$OPTHNeutralMedium confidence
Context

Optimi outlined 2027 plans including a Phase 2b OPTI-101 trial in MDD and a Phase 3 OPTI-201 trial in PTSD, plus a proposed shares-for-debt settlement.

Expected impact

Likely two-sided reaction, with upside from clearer trial execution timelines and downside from dilution/settlement overhang and regulatory uncertainty.

Evidence & confidence

The article provides specific amended trial designs, expected dosing and topline windows, and a concrete share issuance price for settling unpaid compensation, but no trial results or regulatory decisions.

Market effects

Reinforces ongoing development momentum in psychedelic-assisted therapies, but does not change sector-wide regulatory expectations.

Limited, as the key catalysts are Canada/US trial planning and Australia supply arrangements.

Low, since the news is company-specific and tied to Health Canada and FDA process steps rather than global policy shifts.

Counterpoint

The timeline is conditional on Health Canada approval and later FDA clearance, so the market may discount the 2027 milestones until regulatory steps are actually completed.

Key entities

  • Optimi Health Corp.

    Subject of the article, outlining 2027 clinical agenda and a proposed shares-for-debt settlement.

  • OPTI-101

    Naturally derived psilocybin candidate for major depressive disorder, planned Phase 2b amended protocol.

  • OPTI-201

    MDMA-based therapy candidate for PTSD, planned Phase 3 trial in 2027.

  • Dane Stevens

    CEO involved in the related-party shares-for-debt settlement for unpaid compensation.

Related articles

$OPTHLow

Optimi Health completes MDMA batch for Canadian phase 3 trial

Optimi Health Corp. (OPTH, OPTI) completed a batch of MDMA capsules for a Canadian Phase 3 PTSD trial, Australian export, and an Israeli clinical trial. The trial, set for 2027, will enroll up to 100 participants. The company has Australian import permits and supplies MDMA for an approved Israeli trial. Optimi's products are not yet authorized by Health Canada.

$SNDKLow

Leopold Aschenbrenner’s AI Fund Cut Its Reported Holdings 92% in One Quarter

Leopold Aschenbrenner's AI fund, Situational Awareness, reduced its reported holdings by 92% to $1.58 billion in Q3, according to 13F filings. The fund sold stakes in SanDisk, Micron, Bloom Energy, Nebius, and CoreWeave, shifting into options. New top holding is SharonAI at $441 million. Micron and SanDisk reported revenue growth, while Bloom raised guidance. CoreWeave and Nebius faced financial challenges.